Evidence map›Paper›PMID 31115546›Full record

ArticleOncology reports2019

Engineered human mesenchymal stem cells for neuroblastoma therapeutics.

Valentina Nieddu, Roberta Piredda, Daniel Bexell, Jack Barton, John Anderson, Neil Sebire, Krishna Kolluri, Sam M Janes, Emmanouil Karteris, Arturo Sala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valentina NiedduDepartment of Life Sciences, Research Institute of Environment, Health and Societies, Brunel University London, Uxbridge, Middlesex UB8 3PH, UK.
Roberta PireddaDepartment of Life Sciences, Research Institute of Environment, Health and Societies, Brunel University London, Uxbridge, Middlesex UB8 3PH, UK.
Daniel BexellDepartment of Laboratory Medicine, Translational Cancer Research, Lund University, SE-221 00 Lund, Sweden.
Jack BartonInstitute of Child Health, Unit of Molecular Haematology and Cancer Biology, University College London, London WC1N 1EH, UK.
John AndersonInstitute of Child Health, Unit of Molecular Haematology and Cancer Biology, University College London, London WC1N 1EH, UK.
Neil SebireDevelopmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Krishna KolluriLungs for Living Research Centre, UCL Respiratory, University College London, London WC1E 6JF, UK.
Sam M JanesLungs for Living Research Centre, UCL Respiratory, University College London, London WC1E 6JF, UK.
Emmanouil KarterisDepartment of Life Sciences, Research Institute of Environment, Health and Societies, Brunel University London, Uxbridge, Middlesex UB8 3PH, UK.
Arturo SalaDepartment of Life Sciences, Research Institute of Environment, Health and Societies, Brunel University London, Uxbridge, Middlesex UB8 3PH, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-resistant neuroblastoma remains a major challenge in paediatric oncology and novel and less toxic therapeutic approaches are urgently needed to improve survival and reduce the side effects of traditional therapeutic interventions. Mesenchymal stem cells (MSCs) are an attractive candidate for cell and gene therapy since they are recruited by and able to infiltrate tumours. This feature has been exploited by creating genetically modified MSCs that are able to combat cancer by delivering therapeutic molecules. Whether neuroblastomas attract systemically delivered MSCs is still controversial. We investigated whether MSCs engineered to express tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) could: i) cause death of classic and primary neuroblastoma cell lines in vitro; ii) migrate to tumour sites in vivo; and iii) reduce neuroblastoma growth in xenotransplantation experiments. We observed that classic and primary neuroblastoma cell lines expressing death receptors could be killed by TRAIL-loaded MSCs in vitro. When injected in the peritoneum of neuroblastoma-bearing mice, TRAIL-MSCs migrated to tumour sites, but were unable to change the course of cancer development. These results indicated that MSCs have the potential to be used to deliver drugs in neuroblastoma patients, but more effective biopharmaceuticals should be used instead of TRAIL.

Indexed as

AnimalsApoptosisCell Line, TumorCells, CulturedCoculture TechniquesFemaleGenetic EngineeringHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceNeuroblastomaReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandXenograft Model Antitumor AssaysReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTNFRSF10A protein, humanTNFRSF10B protein, humanTNFSF10 protein, human

Identifiers

PMID31115546
PMCPMC6549104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.